================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
----------
SCHEDULE 14D-9
(AMENDMENT NO. 1)
SOLICITATION/RECOMMENDATION STATEMENT UNDER
SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934
----------
EXEGENICS INC.
(NAME OF SUBJECT COMPANY)
EXEGENICS INC.
(NAME OF PERSON FILING STATEMENT)
COMMON STOCK, PAR VALUE $0.01 PER SHARE
SERIES A CONVERTIBLE PREFERRED STOCK, PAR VALUE $0.01 PER SHARE
(TITLE OF CLASS OF SECURITIES)
301610 (COMMON STOCK)
(CUSIP NOT APPLICABLE FOR PREFERRED STOCK)
(CUSIP NUMBER OF CLASS OF SECURITIES)
----------
RONALD L. GOODE, PH.D.
EXEGENICS INC.
2110 RESEARCH ROW
DALLAS, TEXAS 75235
(214) 358-2000
(NAME, ADDRESS AND TELEPHONE NUMBER OF PERSON AUTHORIZED TO RECEIVE NOTICE AND
COMMUNICATIONS ON BEHALF OF THE PERSON FILING STATEMENT)
----------
COPY TO:
JOEL I. PAPERNIK, ESQ.
MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO, P.C.
666 THIRD AVENUE
24TH FLOOR
NEW YORK, NEW YORK 10017
(212) 935-3000
[ ] Check the box if the filing relates solely to preliminary communications
made before the commencement of a tender offer.
================================================================================
This Amendment No. 1 amends and supplements the Solicitation/
Recommendation Statement on Schedule 14D-9 initially filed with the Securities
and Exchange Commission on June 12, 2003 (the "Schedule 14D-9"), by eXegenics
Inc., a Delaware corporation ("eXegenics"), relating to the tender offer made by
EI Acquisition Inc., (the "Purchaser"), a Delaware corporation and wholly-owned
subsidiary of Foundation Growth Investments LLC, a Delaware limited liability
company and a private investment fund, as set forth in a Tender Offer Statement
filed by the Purchaser on Schedule TO, dated May 29, 2003 (as subsequently
amended, the "Schedule TO"), for all of the outstanding common stock, par value
$0.01 per share, of eXegenics, and Series A Convertible Preferred Stock, par
value $0.01 per share of eXegenics (together, the "Shares"), at a price of $0.40
per Share, net to the seller in cash, upon the terms and subject to the
conditions set forth in the Schedule TO. Unless otherwise indicated, all
capitalized terms used but not defined herein shall have the meanings ascribed
to them in the Schedule 14D-9.
ITEM 8. ADDITIONAL INFORMATION.
Item 8 of the Schedule 14D-9 is hereby amended to add the following:
The information set forth in Exhibit 6 filed herewith is incorporated
herein by reference.
ITEM 9. EXHIBITS.
Item 9 of the Schedule 14D-9 is hereby amended by adding the following
thereto:
EXHIBIT NO.
-----------
Exhibit 6. Press Release issued by eXegenics on June 17, 2003.
2
SIGNATURE
After due inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.
EXEGENICS INC.
By: /s/ RONALD L. GOODE
-------------------------------------
RONALD L. GOODE
CHAIRMAN, CHIEF EXECUTIVE OFFICER AND
PRESIDENT
Dated: June 17, 2003
INDEX TO EXHIBITS
EXHIBIT
NUMBER DESCRIPTION
------- -----------
6 Press Release issued by eXegenics on June 17, 2003.